CoolSculpting the Flanks

Body Fat Disorder Clinical Trial

— CSI  

Official title:

CoolSculpting the Flanks

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03304925
• Other study ID #: ZA17-002
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 25, 2017
• Est. completion date: August 2022

Study information

• Verified date: August 2020
• Source: Zeltiq Aesthetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction in the flanks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 320
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria

• Male or female subjects > 22 years of age and < 65 years of age.

• Subject has clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment.

• No weight change exceeding 5% of body weight in the preceding month.

• Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.

• Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the course of the study.

• Subject has read and signed the study written informed consent form.

Exclusion Criteria

• Subject has had a surgical procedure(s) in the area of intended treatment.

• Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.

• Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months.

• Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.

• Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.

• Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.

• Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.

• Subject is taking or has taken diet pills or supplements within the past month.

• Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).

• Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system

• Subject is pregnant or intending to become pregnant during the study period (in the next 8 months).

• Subject is lactating or has been lactating in the past 6 months.

• Subject has a history of hernia in the areas to be treated.

• Subject is unable or unwilling to comply with the study requirements.

• Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

• Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Related Conditions & MeSH terms

• Body Fat Disorder
• Lipid Metabolism Disorders

Intervention

Device:
• The ZELTIQ System
The CoolSculpting machine will be used to perform the treatments.

Locations

Country	Name	City	State
United States	SkinCare Physicians of Chestnut Hill	Chestnut Hill	Massachusetts
United States	EpiCenter Skincare and Laser Center	Dallas	Texas
United States	Zel Skin & Laser Specialist	Edina	Minnesota
United States	Brian S. Biesman, MD	Nashville	Tennessee
United States	Laser & Skin Surgery Center of New York	New York	New York
United States	Innovation Research Center	Pleasanton	California
United States	Laser & Skin Surgery Center of Northern California	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Zeltiq Aesthetics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety endpoint in relation to adverse events	Measurement of device- or procedure-related adverse events. It is expected there will be zero UADEs	Final post treatment visit
Primary	Effectiveness endpoint gauged by reduction in fat layer thickness	Reduction in fat layer thickness as measured by ultrasound at the final post-treatment visit.	Final post-treatment visit
Secondary	Subject survey	Subject survey as assessed by questionnaire administered at the final post-treatment visit.	Final post-treatment visit
Secondary	Photo review	Correct identification of pre-treatment vs. final post-treatment visit images by two out of three blinded independent reviewers.	Final post-treatment visit